 Two publicly traded, clinical-stage pharmaceutical companies in Houston worked to better their financial runways Feb. 6 one through a share purchase agreement, the other through a reverse stock split. Houston-based Moleculin Biotech Inc. Nasdaq: MBRX, a clinical-stage pharmaceutical company targeting highly resistant tumors, announced a registered direct offering with institutional investors in a Feb. 6 news release. The agreement allows for Moleculins investors to purchase an aggregate of up to 7.5 million shares and warrants to purchase 5.625 million shares of common stock at a combined public offering price of 80 cents per share. 